×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Module 5: Phase 3 and Regulatory Review
Session Chair(s)
Courtland R. LaVallee, MBA
Executive Director, Project Management
Dynavax Technologies, United States
- Pivotal Efficacy and Safety Studies
- Serious Adverse Effects
- Long-Term Safety
- Drug-Drug Interactions
- Special Populations
- Carcinogenicity Studies